News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Exelixis, Inc. (EXEL) Appoints Executive Vice President And General Counsel



2/13/2014 8:52:44 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced the appointment of Jeffrey J. Hessekiel, J.D., as executive vice president and general counsel. Mr. Hessekiel is a veteran legal professional with more than a decade of experience in the biopharmaceutical industry, as well as six years spent in general corporate and litigation practice in Silicon Valley. His legal expertise in pharmaceutical commercialization, compliance, and risk management will benefit Exelixis following its first product launch and in anticipation of top-line data from as many as four phase 3 pivotal trials later this year.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES